Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (6035)	2/3/1999 4:46:00 PM
From: Jan P	Respond to of 6136

Agouron Reports Consolidated Second Quarter 1999 Net Income February 3, 1999 04:01 PM LA JOLLA, Calif., Feb. 3 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. AGPH today announced consolidated net income of $7,620,000, or $.22 per share, on total revenues of $170,709,000 for the quarter ended December 31, 1998. Total sales of the company's HIV protease inhibitor, VIRACEPT(R) (nelfinavir mesylate), were $158,193,000, including $112,600,000 in North American sales, a 33% increase from the same period a year ago. Prior year results for the same period were a net income of $4,922,000, or $.15 per share, on total revenues of $104,662,000. "Results of the company's non-oncology operations, which would have been reported separately today had we not previously announced our plan to merge with Warner-Lambert, were net income of $19,096,000, or $.56 per share, on total revenues of $170,580,000 for the quarter," said Peter Johnson, Agouron's president and chief executive officer. Jan